Skip to the page

Data / Drug companies / Almirall, LLC

Almirall, LLC: 15 products in the FDA NDC directory, labeler code 16110

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Almirall, LLC (labeler code 16110) lists 15 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 12 prescription drugs, 3 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on December 14, 2020.

The request: Watch Almirall, LLC (FDA labeler code 16110): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
16110
Products in commercial distribution
15
Packages
23
Finished drugs by generic name
7
Prescription products
12
Over the counter products
0
Flagged as original packager
12 of 12 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
May 31, 2018
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)1280%
Drugs for further processing320%

Products by type

TypeProductsShare
Prescription drugs1280%
Drugs for further processing320%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Tazarotene410
Sarecycline hydrochloride31
Tirbanibulin11
Doxycycline hyclate161
Dapsone126
Azelaic acid111
Flurandrenolide15

Dosage forms

Dosage formProductsShare
Tablet, coated640%
Gel320%
Cream320%
Ointment16.7%
Capsule16.7%
Tape16.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Klisyri16110-391OintmentNew drug applications (NDA)December 14, 2020
Tazorac16110-833GelNew drug applications (NDA)February 21, 2020
Tazorac16110-042GelNew drug applications (NDA)February 21, 2020
Tazorac16110-916CreamNew drug applications (NDA)February 3, 2020
Tazorac16110-915CreamNew drug applications (NDA)February 3, 2020
Aczone16110-526GelNew drug applications (NDA)September 10, 2019
Seysara16110-247Tablet, coatedNew drug applications (NDA)January 4, 2019
Sarecycline hydrochloride16110-247Tablet, coatedDrugs for further processingJanuary 4, 2019
Sarecycline hydrochloride16110-246Tablet, coatedDrugs for further processingJanuary 4, 2019
Seysara16110-246Tablet, coatedNew drug applications (NDA)January 4, 2019
Seysara16110-245Tablet, coatedNew drug applications (NDA)January 4, 2019
Sarecycline hydrochloride16110-245Tablet, coatedDrugs for further processingJanuary 4, 2019
Azelex16110-869CreamNew drug applications (NDA)September 24, 2018
Cordran16110-587TapeNew drug applications (NDA)September 24, 2018
Acticlate CAP16110-601CapsuleNew drug applications (NDA)May 31, 2018

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.